Trials / Completed
CompletedNCT00460408
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
European Epidemiologic COHORT Study: A Prospective Epidemiologic COHORT Study Of Ocular Safety In Patients Receiving Macugen Injections For Neovascular Age-Related Macular Degeneration (AMD) In Europe
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 501 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will provide additional safety data for specific safety events in persons receiving intravitreal injections. The Committee for Medicinal Products for Human Use (CHMP) is interested in obtaining additional safety information when Macugen is used in real world settings by practitioners in Europe treating patients with neovascular (wet) age-related macular degeneration (AMD). The study will provide information about physician practice patterns and characteristics of patients treated with Macugen.
Detailed description
No comparator Patients with age-related macular degeneration
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Macugen | Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks. |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2012-02-01
- Completion
- 2012-02-01
- First posted
- 2007-04-16
- Last updated
- 2012-12-11
- Results posted
- 2012-12-11
Locations
68 sites across 13 countries: Belgium, Cyprus, Czechia, Denmark, France, Germany, Greece, Ireland, Italy, Poland, Slovakia, Spain, Sweden
Source: ClinicalTrials.gov record NCT00460408. Inclusion in this directory is not an endorsement.